



pharmadvances

THE OFFICIAL JOURNAL OF SOCIETÀ ITALIANA DI FARMACOLOGIA

SPECIAL ISSUE

**Opinion Papers by
SIF & Farindustria**

**THE VALUE OF THE
PARTNERSHIP BETWEEN
THE PHARMACEUTICAL
INDUSTRY AND THE ITALIAN
SOCIETY OF PHARMACOLOGY
FOR INNOVATION AND
SUSTAINABILITY**

EDITOR IN CHIEF

Luca Pani

EXECUTIVE EDITOR

Francesco Visioli

SECTION EDITORS

Elisabetta Cerbai
Gilberto Corbellini
Claes Wahlestedt

MANAGEMENT COMMITTEE

Monica Di Luca
Chairman of the Management Committee
Ludovico Baldessin
Alessandro Mugelli
Giorgio Racagni

ADVISORY BOARD

Liberato Berrino
Alessandra Bitto
Giambattista Bonanno
Nicoletta Brunello
Giorgio Cantelli Forti
Annalisa Capuano
Christian Chiamulera
Gaiddon Christian
Giuseppe Cirino
Emilio Clementi
Salvatore Cuzzocrea
Antonio D'Avolio
Romano Danesi
Annamaria De Luca
Giovambattista De Sarro
Marzia Del Re
Armando Genazzani
Carla Ghelardini
Gualberto Gussoni
Patrizia Hrelia
Pierre Magistretti
Marco Pistis
Gianni Sava
Francesco Scaglione
Maria Angela Sortino
Maurizio Tagliatalata
Luigia Trabace
Gianluca Trifirò

CHIEF BUSINESS & CONTENT OFFICER

Ludovico Baldessin

PUBLISHING EDITOR


Elisa Grignani
e.grignani@lswr.it
Ph. 039 (0)2-88184.101

PRODUCTION MANAGER

Paolo Ficicchia
p.ficicchia@lswr.it
Ph. 0039 (0)2-88184.222

SALES & REPRINTS

Federica Rossi
Business Operations Manager
dircom@lswr.it
reprints@lswr.it
Ph. 0039 (0)2-88184.404



This Special Issue is the result of a translation from "Quaderni della SIF" (ISSN 2039-9561), volume 1 – February 2022, titled: *"Il valore della partnership tra industria farmaceutica e Società Italiana di Farmacologia per l'innovazione e la sostenibilità"*.

The opinions expressed in this publication are those of the authors and not necessarily the position of the Italian Society of Pharmacology (SIF).

TABLE OF CONTENTS

SUMMARY

PREFACE.....	4
INTRODUCTION	
G. Racagni, N. Martini, M. Zibellini	5
New clinical research methods to ensure patients’ rapid access to treatments	
L. Bergamini, M. Scatigna, D. Valle, R. Danesi.....	9
Quality of scientific data in pre and post-authorisation clinical drug trials	
A. M. Porrini, G. Trifirò, M. Mangrella, D. Valle, L. Berrino, M. Simonato	20
The patient and their treatment needs	
M. Mangrella, A. De Luca, A. Capuano, N. Martini, C. Piccinni	32
<i>Breakthrough</i> innovation, diagnostic, therapeutic and treatment processes and impact on chronicity	
G. Panina, A. Capuano, C. Piccinni, M. Mangrella, C. Chiamulera, A. De Luca, G. D. Norata, N. Martini	45
Digital innovation in medicine: from <i>Digital Health</i> to <i>Digital Therapeutics</i>	
D. Valle, G. Minotti, G. D. Norata, A. M. Porrini	55
Dynamic scientific communication to support patient choice and innovation in medicine	
L. Franzini, G. Sava, M. Mangrella, G. Cirino	64
Executive summary	71

PREFACE

Doi: 10.36118/pharmadvances.2022.35

This document, structured around the contributions of different working groups, stems from the observations that emerged during the regular SIF-Farindustria table meetings held during 2020-2021, as well as from the 40th National Congress of the Italian Society of Pharmacology (March 9-13, 2021).

The document was edited by the Editorial Committee consisting of:

Carlo Piccinni (coordinator) - Research and Health Foundation (ReS), Rome, Italy

Daniilo Norata - Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy

Cristiano Chiamulera - Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Laura Franzini - Chiesi Medical Management, Parma, Italy